Cracks emerge in US business opposition to India's IPR regime
This article was originally published in Scrip
In what's being viewed as a possible fissure within the US industry that has previously been as one on the need for tough action against India over its "deteriorating" intellectual property rights (IPR) regime, the US-India Business Council (USIBC) has said that it does not believe there is "legal or policy basis" to designate India as a "Priority Foreign Country".
You may also be interested in...
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?